FDA clears RapidAI’s pulmonary embolism triage platform

RapidAI announced today that it received FDA 510(k) clearance for its Rapid PE Triage & Notification product.

San Mateo, California-based RapidAI designed its Rapid PE Triage & Notification product for the fast identification and communication of suspected central pulmonary embolism (PE).

According to a news release, Rapid PE Triage & Notification works in conjunction with RapidAI’s Rapid Workflow for PE offering. Rapid Workflow for PE, which the company designed to align hospital teams on the treatment of patients suspected of having a pulmonary embolism, was launched in June 2021.

The company said its newly cleared platform will enable care teams to more easily manage the entire patient care journey from the moment a suspected PE patient is identified to diagnosis and through treatment. Patients can be triaged faster and care teams can be aligned more quickly to reduce the overall time to treatment thanks to the automatic identificati…

Read more
  • 0

RapidAI launches workflow platform for pulmonary embolism

RapidAI announced today that it launched its mobile and web-based app to aid in the treatment of pulmonary embolism (PE).

San Mateo, Calif.-based RapidAI made available the Rapid Workflow for PE, which it designed to align hospital teams on the treatment of patients suspected of having a pulmonary embolism, according to a news release.

Rapid Workflow for PE helps hospital teams align, activate and communicate about patient status to ensure faster care, reducing the time to treatment, improving care coordination and optimizing protocols through the collection of patient status data.

“Rapid Workflow for PE is the next step in our journey to improving patient care,” RapidAI CEO Don Listwin said in the release. “When it comes to acute vascular diseases, time is of the essence. That’s why we’ve created an extensible platform that addresses the specific needs of care teams across vascular and neurovascular conditions, providing these teams with the tools they …

Read more
  • 0

FDA clears RapidAI blood clot detector

RapidAI announced today that it received FDA clearance for its Rapid LVO system for detecting suspected large vessel occlusions (LVOs).

Menlo Park, Calif.-based RapidAI’s Rapid LVO is designed to help physicians speed up triage or transfer decision making. The system uses a vessel tracker, along with an assessment of brain regions with reduced blood vessel density to identify suspected LVOs in as few as three minutes before immediately notifying stroke team members, according to a news release.

According to the company, which touts the system as the “gold standard” of cerebrovascular imaging, Rapid LVO can identify suspected LVOs with a sensitivity of 97%, as well as a specificity of 96%.

“LVOs are the most disabling and deadly ischemic strokes,” Stanford University professor of neurology, director of the Stanford Stroke Center & RapidAI co-founder Dr. Greg Albers said in the release. “The ability to identify LVOs rapidly facilitate…

Read more
  • 0